In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 5, 2009, Pages 679-686

  Bolenz, Christian ^a   Weiss, Christel ^b   Wenzel, Melanie ^a   Gabriel, Ute ^a   Steidler, Annette ^a   Becker, Andreas ^a   Herrmann, Edwin ^c   Trojan, Lutz ^a   Michel, Maurice Stephan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Animal models; Antineoplastic combined chemotherapy protocols; Antisense oligodeoxyribonucleotides; Intravesical instillations; Paclitaxel; Transitional cell carcinoma

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PROTEIN BCL XL; PROTEIN BCL XL ANTISENSE OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; BODY WEIGHT; CANCER TRANSPLANTATION; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; NUDE RAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL ANALYSIS; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR VOLUME; UMUC 3 CELL; URINALYSIS; WESTERN BLOTTING;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BCL-X PROTEIN; CARCINOMA; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; RATS; RATS, NUDE; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 63549133341     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0500-5     Document Type: Article

References (30)

1. JL Au J Kalns Y Gan MG Wientjes 1997 Pharmacologic effects of paclitaxel in human bladder tumors Cancer Chemother Pharmacol 41 69 74 10.1007/ s002800050709
2. C Bolenz A Becker L Trojan A Schaaf Y Cao C Weiss 2007 Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides Urol Oncol 25 476 482 10.1016/j.urolonc.2007.01. 017
3. C Bolenz M Wenzel Y Cao L Trojan A Hacker MF Arancibia 2007 Newly developed mini-endoscope for diagnosis and follow-up of orthotopic bladder transitional-cell carcinoma in vivo J Endourol 21 789 794 10.1089/end.2006.0355
4. MF Botteman CL Pashos A Redaelli B Laskin R Hauser 2003 The health economics of bladder cancer: a comprehensive review of the published literature Pharmacoeconomics 21 1315 1330 10.2165/00019053-200321180-00003
5. BJ Duggan S Gray SR Johnston K Williamson H Miyaki M Gleave 2002 The role of antisense oligonucleotides in the treatment of bladder cancer Urol Res 30 137 147 10.1007/s00240-002-0248-3
6. S Fuessel A Meye K Kraemer D Kunze OW Hakenberg MP Wirth 2007 Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma Eur Urol 51 315 326 10.1016/j.eururo.2006.07.045 discussion 326-317
7. AJ Glackin SB Gray SR Johnston BJ Duggan KE Williamson 2005 Antisense oligonucleotides in the treatment of bladder cancer Expert Opin Biol Ther 5 67 77 10.1517/14712598.5.1.67
8. HB Grossman G Wedemeyer L Ren GN Wilson B Cox 1986 Improved growth of human urothelial carcinoma cell cultures J Urol 136 953 959
9. BA Hadaschik MG ter Borg J Jackson RD Sowery AI So HM Burt 2008 Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer BJU Int 101 1347 1355 10.1111/j.1464-410X.2008.07571.x
10. JA Hickman 1996 Apoptosis and chemotherapy resistance Eur J Cancer 32A 921 926 10.1016/0959-8049(96)00080-9
11. JH Hong E Lee J Hong YJ Shin H Ahn 2002 Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines BJU Int 90 113 117 10.1046/j.1464-410X.2002.02799.x
12. S Hopkins-Donaldson R Cathomas AP Simoes-Wust S Kurtz L Belyanskaya RA Stahel 2003 Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment Int J Cancer 106 160 166 10.1002/ijc.11209
13. S Koga Y Kondo T Komata S Kondo 2001 Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA Gene Ther 8 654 658 10.1038/sj.gt.3301449
14. P Korkolopoulou A Lazaris AE Konstantinidou N Kavantzas E Patsouris P Christodoulou 2002 Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival Eur Urol 41 274 283 10.1016/S0302-2838(02)00003-9
15. D Kunze D Wuttig I Kausch C Blietz L Blumhoff Y Burmeister 2008 Antisense-mediated inhibition of surviving, hTERT and VEGF in bladder cancer cells in vitro and in vivo Int J Oncol 32 1049 1056
16. AH Kyle LA Huxham DM Yeoman AI Minchinton 2007 Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors Clin Cancer Res 13 2804 2810 10.1158/1078-0432.CCR-06-1941
17. C Le Visage N Rioux-Leclercq M Haller P Breton B Malavaud K Leong 2004 Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer J Urol 171 1324 1329 10.1097/01.ju.0000103922.12319. 59
18. I Lebedeva A Raffo R Rando J Ojwang P Cossum CA Stein 2001 Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides J Urol 166 461 469 10.1016/S0022-5347(05)65964-2
19. JM McKiernan P Masson AM Murphy M Goetzl CA Olsson DP Petrylak 2006 Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy J Clin Oncol 24 3075 3080 10.1200/JCO.2005.03.1161
20. RE Meyn LC Stephens L Milas 1996 Programmed cell death and radioresistance Cancer Metastasis Rev 15 119 131 10.1007/BF00049491
21. H Miyake H Eto I Hara A So D Li ME Gleave 2004 Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells J Urol 171 2477 2481 10.1097/01.ju.0000118382.89456.f7
22. H Miyake K Yamanaka M Muramaki I Hara ME Gleave 2005 Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model Neoplasia 7 171 179 10.1593/neo.04478
23. T Miyashita JC Reed 1993 Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line Blood 81 151 157
24. O Nativ M Aronson O Medalia T Moldavsky E Sabo I Ringel 1997 Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies Int J Cancer 70 297 301 10.1002/(SICI)1097-0215(19970127)70:3<297::AID-IJC9>3.0.CO;2-S
25. A Schaaf S Sagi S Langbein L Trojan P Alken MS Michel 2004 Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides Urol Oncol 22 188 192 10.1016/j.urolonc.2004.01.010
26. D Song MG Wientjes JL Au 1997 Bladder tissue pharmacokinetics of intravesical taxol Cancer Chemother Pharmacol 40 285 292 10.1007/s002800050660
27. RJ Sylvester W Oosterlinck AP van der Meijden 2004 A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2186 2190 10.1097/01.ju.0000125486. 92260.b2 quiz 2435
28. RJ Sylvester W Oosterlinck JA Witjes 2008 The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials Eur Urol 53 709 719 10.1016/j.eururo.2008.01.015
29. JQ Yin J Gao R Shao WN Tian J Wang Y Wan 2003 siRNA agents inhibit oncogene expression and attenuate human tumor cell growth J Exp Ther Oncol 3 194 204 10.1046/j.1359-4117.2003.01092.x
30. Q Zhao R Zhou J Temsamani Z Zhang A Roskey S Agrawal 1998 Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice Antisense Nucleic Acid Drug Dev 8 451 458